Integrative Analysis of Large-cell Lung Cancer
Recruiting
- Conditions
- Lung Cancer
- Interventions
- Other: Normal lung tissue
- Registration Number
- NCT02917369
- Lead Sponsor
- Shanghai 10th People's Hospital
- Brief Summary
Integrative analysis of LCLC
- Detailed Description
The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Age ≤ 75 years with histologically proven LCLC
- No severe major organ dysfunction
- World Health Organization (WHO) performance status of 0 or 1
- No prior cancer chemotherapy
Exclusion Criteria
- Age ≥ 76
- Severe major organ dysfunction
- WHO performance status of >1
- Prior cancer chemotherapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Metastasis tissues Normal lung tissue Metastasis tissues from LCLC patients Normal lung tissue Normal lung tissue Normal lung tissue from LCLC patients LCLC tissues Normal lung tissue LCLC tissues from LCLC patients
- Primary Outcome Measures
Name Time Method 5 years overall survival 5 years
- Secondary Outcome Measures
Name Time Method 5 years disease-free survival 5 years
Trial Locations
- Locations (3)
Ganzhou City People's Hospital
🇨🇳Ganzhou, Jiangxi, China
Shanghai Tenth People's Hospital
🇨🇳Shanghai, Shanghai, China
Shanghai Pulmonary Hospital
🇨🇳Shanghai, Shanghai, China